Key result
An in utero management strategy including dexamethasone and targeted delivery resulted in 0 fetal deaths among 29 fetuses with immune-mediated 2° or 3° atrioventricular block.
Why the study?
Does a structured in utero management strategy improve perinatal outcomes in fetuses with immune-mediated atrioventricular block?
Population
29 fetuses with immune-mediated 2° (n=6) or 3° (n=23) atrioventricular (AV) block.
Design
Case_series
Follow-up
perinatal period
Authors
Loading...
May support in utero dexamethasone in select fetal AV block cases; leaves open confirmation in prospective trials.
Observational (n=29)
Does a structured in utero management strategy improve perinatal outcomes in fetuses with immune-mediated atrioventricular block?
A structured in utero management strategy incorporating monitoring, transplacental dexamethasone, and targeted therapies resulted in 100% perinatal survival in fetuses with immune-mediated AV block.
Cuneo et al. (2010) conducted an observational in immune-mediated 2° or 3° atrioventricular (AV) block (n=29). In utero management strategy was evaluated on fetal deaths. An in utero management strategy including dexamethasone and targeted delivery resulted in 0 fetal deaths among 29 fetuses with immune-mediated 2° or 3° atrioventricular block.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: